Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein (HSIC) delivers essential healthcare products and services to dental, medical, and animal health practices worldwide. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and strategic initiatives.
Track all official announcements through our curated collection of press releases and verified news coverage. Stay informed about earnings reports, product launches, partnership agreements, and operational milestones that shape Henry Schein's position in global healthcare distribution.
Key updates include acquisitions expanding service capabilities, technological innovations in supply chain management, and regulatory developments affecting medical device distribution. Our repository eliminates fragmented research by consolidating critical information from multiple sources.
Bookmark this page for efficient monitoring of HSIC's market activities. Return regularly to access new filings, leadership updates, and analysis of trends impacting healthcare providers and distributors.
Henry Schein (Nasdaq: HSIC), the leading provider of healthcare products and services to dental and medical practitioners, has announced a new $750 million share repurchase program. This initiative comes in addition to the company's existing $500 million repurchase program announced in January 2025.
The new authorization represents approximately 9.0% of outstanding shares at the current stock price, with the company having 118.6 million shares outstanding as of September 8, 2025. The purchases will be conducted through open market or negotiated transactions, demonstrating management's confidence in their 2025-2027 BOLD+1 Strategic Plan.
Henry Schein Medical (NASDAQ:HSIC) has expanded its SolutionsHub by partnering with Colaborate, a management consulting firm specializing in medical laboratory services. The collaboration aims to enhance clinical laboratory operations across the United States by combining Colaborate's consulting expertise with Henry Schein's extensive network and capabilities.
Colaborate, established in 2005, has served over 500 institutions with services including billing, compliance assessments, consolidation assessments, and performance enhancements. The partnership will help laboratories address financial pressures and regulatory demands while improving operational efficiency and financial sustainability.
Henry Schein (NASDAQ:HSIC), the world's largest provider of healthcare solutions for dental and medical practitioners, has announced its participation in three major investor conferences in September 2025.
The company will present at the Wells Fargo Healthcare Conference in Boston on September 4, the Baird Global Healthcare Conference in New York City on September 10, and the Bank of America Global Healthcare Conference in London on September 24. All presentations will be accessible via live webcast on the company's website, with replays available afterward.
Henry Schein (Nasdaq: HSIC) has launched its 28th annual "Back to School" program, a global corporate citizenship initiative benefiting over 5,200 students across 45 locations in the U.S., Canada, Italy, Spain, the U.K., and Ireland.
The program, which has helped more than 75,000 children since 1998, involves Team Schein Members (TSMs) partnering with non-profit organizations to provide backpacks filled with school supplies and oral hygiene kits to underserved children. At the company's headquarters event in Melville, N.Y., 400 pre-identified students received backpacks, supplies, and gift cards for school outfits, alongside enjoying family activities and accessing free books donated through partnerships with KPMG LLP and First Book.
Henry Schein (NASDAQ: HSIC) reported its Q2 2025 financial results, with total net sales increasing 3.3% to $3.2 billion. The company's GAAP diluted EPS decreased to $0.70 from $0.80 in Q2 2024, while non-GAAP diluted EPS fell to $1.10 from $1.23.
Key highlights include 1.9% internal sales growth, 0.8% growth from acquisitions, and a 0.6% increase from foreign currency exchange. The company maintained its 2025 guidance, expecting non-GAAP diluted EPS of $4.80-$4.94, sales growth of 2-4%, and mid-single digit Adjusted EBITDA growth.
During Q2, Henry Schein implemented a restructuring plan with expected annual run-rate savings of over $100 million by end-2025, and completed significant share repurchases totaling 3.7 million shares for $259 million.
Henry Schein One (NASDAQ:HSIC) has launched Forms, a digital intake solution for Dentrix and Dentrix Ascend platforms, with over 1,000 dental practices adopting it in the first month. The solution features mobile-friendly customizable forms, ID and insurance card scanning, and secure two-factor authentication for virtually touchless patient check-in.
Early adoption data shows 90% form completion rates by patients, streamlining the pre-appointment process. The platform includes multilingual support, automated data integration, and centralized form management for dental service organizations (DSOs). Forms is available as part of standard Ascend upgrades and included in Patient Engage and Lighthouse packages, with separate pricing options for Dentrix users.
Henry Schein (Nasdaq: HSIC), the leading provider of healthcare solutions for dental and medical practitioners, has scheduled its Q2 2025 earnings release and conference call for Tuesday, August 5, 2025. The financial results will be released before market open, followed by a live webcast at 8:00 a.m. ET.
The earnings call will feature presentations from Chairman and CEO Stanley M. Bergman and CFO Ronald N. South. Investors can access the webcast through the company's investor relations website, with a replay available after the presentation.
Henry Schein (Nasdaq: HSIC) announced that CEO Stanley M. Bergman will retire at the end of 2025 after an impressive 45-year tenure, including over 35 years as CEO. Bergman will continue as Chairman after retirement while the Board initiates a formal search for his successor, considering both internal and external candidates.
Under Bergman's leadership, Henry Schein transformed from a small U.S. dental mail order company into a global healthcare solutions giant, growing revenue from $225 million in 1989 to nearly $13 billion in 2024 (17.5% CAGR). The company's market cap expanded from $290 million at its 1995 IPO to approximately $9 billion currently, delivering a 12.4% non-GAAP EPS CAGR.
The company has evolved into the largest global dental distributor, leading provider of dental practice management software, and second-largest provider of endodontic products, with higher-margin businesses now contributing over 50% of total non-GAAP operating income.
Henry Schein One (HSIC) has released its fourth annual Catalyst Index, a comprehensive report revealing key performance insights from the top 10% of dental practices. The report highlights that leading practices are achieving higher revenue and patient growth despite seeing fewer patients, primarily by focusing on improving patient experience.
Key findings show that nearly 60% of patients decline care due to poor education, pricing clarity, and experience issues. Top performers excel by offering faster appointments, streamlined forms, clear billing, and flexible scheduling. The report indicates that average practices significantly underutilize their revenue potential, with daily gross production approximately four times lower than top performers.